Print Page     Close Window     

SEC Filings

10-K
SERES THERAPEUTICS, INC. filed this Form 10-K on 03/06/2019
Entire Document
 

SERES THERAPEUTICS, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except share and per share data)

 

 

 

December 31,

 

 

 

2018

 

 

2017

 

Assets

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

85,820

 

 

$

36,088

 

Investments

 

 

 

 

 

113,895

 

Prepaid expenses and other current assets

 

 

6,845

 

 

 

5,095

 

Total current assets

 

 

92,665

 

 

 

155,078

 

Property and equipment, net

 

 

26,294

 

 

 

32,931

 

Restricted investments

 

 

1,400

 

 

 

1,400

 

Restricted cash

 

 

113

 

 

 

113

 

Total assets

 

$

120,472

 

 

$

189,522

 

Liabilities and Stockholder's Equity (Deficit)

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

6,415

 

 

$

7,033

 

Accrued expenses and other current liabilities

 

 

15,207

 

 

 

12,513

 

Deferred revenue - related party

 

 

20,419

 

 

 

12,079

 

Total current liabilities

 

 

42,041

 

 

 

31,625

 

Lease incentive obligation, net of current portion

 

 

7,250

 

 

 

8,989

 

Deferred rent

 

 

2,216

 

 

 

2,233

 

Deferred revenue, net of current portion - related party

 

 

116,840

 

 

 

84,847

 

Other long-term liabilities

 

 

170

 

 

 

1,129

 

Total liabilities

 

 

168,517

 

 

 

128,823

 

Commitments and contingencies (Note 11)

 

 

 

 

 

 

 

 

Stockholders’ equity (deficit):

 

 

 

 

 

 

 

 

Preferred stock, $0.001 par value; 10,000,000 shares authorized at December 31, 2018

   and 2017; no shares issued and outstanding at December 31, 2018 and 2017

 

 

 

 

 

 

Common stock, $0.001 par value; 200,000,000 shares authorized at December 31, 2018

    and 2017; 40,936,735 and 40,571,015 shares issued and outstanding

    at December 31, 2018 and 2017

 

 

41

 

 

 

40

 

Additional paid-in capital

 

 

341,284

 

 

 

324,376

 

Accumulated other comprehensive income (loss)

 

 

 

 

 

(146

)

Accumulated deficit

 

 

(389,370

)

 

 

(263,571

)

Total stockholders’ equity (deficit)

 

 

(48,045

)

 

 

60,699

 

Total liabilities and stockholders’ equity (deficit)

 

$

120,472

 

 

$

189,522

 

 

The accompanying notes are an integral part of these consolidated financial statements.

 

 

F-3



© Seres Therapeutics. All Rights Reserved.